On April 30, 2026, BioOrbit, a space manufacturing company developing hardware for the large-scale crystallization of protein drugs, announced the completion of a $13.2 million (£9.8 million) seed round co-led by LocalGlobe and BREEGA, with support from Seedcamp, Auxxo Female Catalyst Fund, Type One Ventures, 7percent Ventures and other investors. Wilson Sonsini Goodrich & Rosati advised BioOrbit on the transaction.

Led by Cambridge scientist Katie King, Ph.D. and Oncology Researcher, Dr. Leonor Teles, BioOrbit's mission is to develop a pharmaceuticals factory in space within the next 10 years.

The Wilson Sonsini team that advised BioOrbit on the transaction includes Dan Glazer, Jose Campos, Rashad Mohammed, and Sophia Kunthara.

For more information, please see BioOrbit's LinkedIn post. Additional coverage can be found on UKTN.